Intravesical bacillus Calmette-Guerin versus mitomycin
C for Ta and T1 bladder cancer.
Such patients have benefitted from bimodality treatment of TURBT followed by concurrent chemoradiation using Mitomycin
Time and dose effects of mitomycin
C on extracellular matrix fibroblasts and proteins.
Efficacy and safety of trabeculectomy with mitomycin
C for childhood glaucoma: A study of results with long-term follow-up.
Role of mitomycin
in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study.
C is a substance isolated from the bacterium Streptomyces caespitosus, which is used as a chemotherapeutic agent and has antiproliferative effects on fibroblasts, reducing fibroblast proliferation and collagen formation.
Her medical history included right breast invasive ductal carcinoma with bilateral mastectomies in 2015, recently diagnosed bladder cancer with TURBT and intravesical mitomycin
C instillation three days prior to current presentation, type 2 diabetes mellitus, hypertension, obstructive sleep apnea, chronic obstructive pulmonary disease, and prothrombin G20210A mutation.
The use of mitomycin
C and other antiproliferative drugs can reduce the recurrence rate, but many complications such as delayed healing of the corneal epithelium and scleral ulcers can also be caused.
Additional therapy may be attempted in patients with refractory strictures, including topical application of mitomycin
C to the stricture site in an attempt to prevent new collagen formation, which decreases the incidence of recurrence.
Clinical and histopathologic observations concerning hypotony after trabeculectomy with adjunctive mitomycin
Hypersensitivity to DNA-crosslinking agent like diepoxybutane (DEB) or mitomycin
C (MMC) is often used as a diagnostic test.Progressive BM failure typically presents in the first decade.Hematologic manifestations in early infancy is rare.
Group 1, group 2, group 3, and group 4 (control) were administered intraperitoneal Mitomycin
C (1 mg/kg) (Kyowa, Hakko, Kogyo, Co., Ltd.), 5 mL 4% Icodextrin (ADEPT[R] Baxter; Deerfield, USA), Mitomycin-C + 4% Icodextrin combination, and 5 mL 0.9% NaCl, respectively.